Ann Liver Transplant.  2024 Nov;4(2):47-55. 10.52604/alt.24.0022.

Resection or transplantation for perihilar cholangiocarcinoma

• Kim J

• KMID: 2561848
• DOI: http://doi.org/10.52604/alt.24.0022

Abstract

An uncommon and aggressive malignancy, perihilar cholangiocarcinoma, may arise in the bile ducts at the intersection of the right and left hepatic ducts. The implementation of surgical resection and transplantation has greatly enhanced the management of the condition, resulting in improved survival rates and enhanced quality of life for patients. Nevertheless, there are still obstacles to overcome, such as restricted therapeutic alternatives for later phases, possible onset of complications, and the scarcity of donor organs. For early-stage illness, surgical resection, typically a right hepatectomy, is the recommended treatment, whereas transplantation is specified for instances that cannot be resected. Liver transplantation provides extended longevity for some patients, but it necessitates lifelong immunosuppression and entails the possibility of recurrence. The choice between resection and transplantation is contingent upon several circumstances, including the stage of the disease, the health of the patient, and the availability of a living liver donor. For patients diagnosed with perihilar cholangiocarcinoma, adopting an interdisciplinary strategy is essential to maximizing treatment success.

Keyword

Survival; Mortality; Hepatectomy; Transplantation; Living donors

Reference

1. Vauthey JN, Dixon E, Abdalla EK, Helton WS, Pawlik TM, Taouli B, et al. American Hepato-Pancreato-Biliary Association. Society of Surgical Oncology. Society for Surgery of the Alimentary Tract. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford). 2010; 12:289–299. DOI: 10.1111/j.1477-2574.2010.00181.x. PMID: 20590901. PMCID: PMC2951814.

2. Baltatzis M, Jegatheeswaran S, Siriwardena AK. 2020; Neoadjuvant chemoradiotherapy before resection of perihilar cholangiocarcinoma: a systematic review. Hepatobiliary Pancreat Dis Int. 19:103–108. DOI: 10.1016/j.hbpd.2020.02.007. PMID: 32147487.

3. Palavecino M, Abdalla EK, Madoff DC, Vauthey JN. 2009; Portal vein embolization in hilar cholangiocarcinoma. Surg Oncol Clin N Am. 18:257–267. viiiDOI: 10.1016/j.soc.2008.12.007. PMID: 19306811.

4. Tustumi F, Ernani L, Coelho FF, Bernardo WM, Junior SS, Kruger JAP, et al. 2018; Preoperative strategies to improve resectability for hepatocellular carcinoma: a systematic review and meta-analysis. HPB (Oxford). 20:1109–1118. DOI: 10.1016/j.hpb.2018.06.1798. PMID: 30057123.

5. Berardi G, Lucarini A, Colasanti M, Mariano G, Ferretti S, Meniconi RL, et al. 2023; Minimally invasive surgery for perihilar cholangiocarcinoma: a systematic review of the short- and long-term results. Cancers (Basel). 15:3048. DOI: 10.3390/cancers15113048. PMID: 37297010. PMCID: PMC10252826.

6. Nimura Y, Hayakawa N, Kamiya J, Kondo S, Shionoya S. 1990; Hepatic segmentectomy with caudate lobe resection for bile duct carcinoma of the hepatic hilus. World J Surg. 14:535–543. discussion 544DOI: 10.1007/BF01658686. PMID: 2166381.

7. Gilbert RWD, Lenet T, Cleary SP, Smoot R, Tzeng CD, Rocha FG, et al. 2022; Does caudate resection improve outcomes of patients undergoing curative resection for perihilar cholangiocarcinoma? A systematic review and meta-analysis. Ann Surg Oncol. 29:6759–6771. DOI: 10.1245/s10434-022-11990-7. PMID: 35705775.

8. Franken LC, Schreuder AM, Roos E, van Dieren S, Busch OR, Besselink MG, et al. 2019; Morbidity and mortality after major liver resection in patients with perihilar cholangiocarcinoma: a systematic review and meta-analysis. Surgery. 165:918–928. DOI: 10.1016/j.surg.2019.01.010. PMID: 30871811.

9. Im JH, Choi GH, Lee WJ, Han DH, Park SW, Bang S, et al. 2021; Adjuvant radiotherapy and chemotherapy offer a recurrence and survival benefit in patients with resected perihilar cholangiocarcinoma. J Cancer Res Clin Oncol. 147:2435–2445. DOI: 10.1007/s00432-021-03524-7. PMID: 33471185.

10. Kamarajah SK, Al-Rawashdeh W, Parente A, Atherton P, Salti GI, Dahdaleh FS, et al. 2022; Adjuvant chemotherapy for perihilar cholangiocarcinoma: a population-based comparative cohort study. Eur J Surg Oncol. 48:1300–1308. DOI: 10.1016/j.ejso.2021.12.002. PMID: 34916085.

11. Nagino M, Ebata T, Yokoyama Y, Igami T, Sugawara G, Takahashi Y, et al. 2013; Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections. Ann Surg. 258:129–140. DOI: 10.1097/SLA.0b013e3182708b57. PMID: 23059502.

12. Govil S, Bharatan A, Rammohan A, Kanagavelu R, Kaliamoorthy I, Reddy MS, et al. 2016; Liver resection for perihilar cholangiocarcinoma - why left is sometimes right. HPB (Oxford). 18:575–579. DOI: 10.1016/j.hpb.2016.05.002. PMID: 27346137. PMCID: PMC4925796.

13. Kawabata Y, Hayashi H, Yano S, Tajima Y. 2017; Liver parenchyma transection-first approach in hemihepatectomy with en bloc caudate lobectomy for hilar cholangiocarcinoma: a safe technique to secure favorable surgical outcomes. J Surg Oncol. 115:963–970. DOI: 10.1002/jso.24612. PMID: 28334429.

14. Kobayashi S, Tomokuni A, Gotoh K, Takahashi H, Akita H, Marubashi S, et al. 2017; A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer. Eur J Surg Oncol. 43:763–771. DOI: 10.1016/j.ejso.2016.12.008. PMID: 28100416.

15. Kimura N, Young AL, Toyoki Y, Wyatt JI, Toogood GJ, Hidalgo E, et al. 2017; Radical operation for hilar cholangiocarcinoma in comparable Eastern and Western centers: outcome analysis and prognostic factors. Surgery. 162:500–514. DOI: 10.1016/j.surg.2017.03.017. PMID: 28551378.

16. Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, et al. 2018; Chemoradiotherapy for initially unresectable locally advanced cholangiocarcinoma. World J Surg. 42:2910–2918. DOI: 10.1007/s00268-018-4558-1. PMID: 29511872.

17. Tran TB, Ethun CG, Pawlik TM, Schmidt C, Beal EW, Fields RC, et al. 2019; Actual 5-year survivors after surgical resection of hilar cholangiocarcinoma. Ann Surg Oncol. 26:611–618. DOI: 10.1245/s10434-018-7075-4. PMID: 30539494.

18. Jo HS, Kim DS, Yu YD, Kang WH, Yoon KC. 2020; Right-side versus left-side hepatectomy for the treatment of hilar cholangiocarcinoma: a comparative study. World J Surg Oncol. 18:3. DOI: 10.1186/s12957-019-1779-1. PMID: 31901228. PMCID: PMC6942359.

19. Jeddou H, Tzedakis S, Orlando F, Robert A, Meneyrol E, Bergeat D, et al. 2022; Liver resection for type IV perihilar cholangiocarcinoma: left or right trisectionectomy? Cancers (Basel). 14:2791. DOI: 10.3390/cancers14112791. PMID: 35681768. PMCID: PMC9179267.

20. Olthof PB, Erdmann JI, Alikhanov R, Charco R, Guglielmi A, Hagendoorn J, et al. Perihilar Cholangiocarcinoma Collaboration Group. Higher postoperative mortality and inferior survival after right-sided liver resection for perihilar cholangiocarcinoma: left-sided resection is preferred when possible. Ann Surg Oncol. 2024; 31:4405–4412. DOI: 10.1245/s10434-024-15115-0. PMID: 38472674. PMCID: PMC11164810.

21. Andraus W, Tustumi F, Santana AC, Pinheiro RSN, Waisberg DR, Lopes LD, et al. 2024; Liver transplantation as an alternative for the treatment of perihilar cholangiocarcinoma: a critical review. Hepatobiliary Pancreat Dis Int. 23:139–145. DOI: 10.1016/j.hbpd.2024.01.003. PMID: 38310060.

22. Ahmed O, Vachharajani N, Chang SH, Park Y, Khan AS, Chapman WC, et al. 2022; Single-center experience of liver transplantation for perihilar cholangiocarcinoma. HPB (Oxford). 24:461–469. DOI: 10.1016/j.hpb.2021.08.940. PMID: 34465528.

23. Vugts JJA, Gaspersz MP, Roos E, Franken LC, Olthof PB, Coelen RJS, et al. 2021; Eligibility for liver transplantation in patients with perihilar cholangiocarcinoma. Ann Surg Oncol. 28:1483–1492. DOI: 10.1245/s10434-020-09001-8. PMID: 32901308. PMCID: PMC7892510.

24. Ilyas SI, Gores GJ. 2013; Pathogenesis, diagnosis, and management of cholangiocarcinoma. Gastroenterology. 145:1215–1229. DOI: 10.1053/j.gastro.2013.10.013. PMID: 24140396. PMCID: PMC3862291.

25. Keltner SJ, Hallemeier C, Wang K, Tao R, Shah S, Heimbach J, et al. 2023; Neoadjuvant therapy regimens for hilar cholangiocarcinoma before liver transplant. Am J Clin Oncol. 46:276–278. DOI: 10.1097/COC.0000000000001002. PMID: 37036238.

26. Zamora-Valdes D, Heimbach JK. 2018; Liver transplant for cholangiocarcinoma. Gastroenterol Clin North Am. 47:267–280. DOI: 10.1016/j.gtc.2018.01.002. PMID: 29735023.

27. Loveday BPT, Knox JJ, Dawson LA, Metser U, Brade A, Horgan AM, et al. 2018; Neoadjuvant hyperfractionated chemoradiation and liver transplantation for unresectable perihilar cholangiocarcinoma in Canada. J Surg Oncol. 117:213–219. DOI: 10.1002/jso.24833. PMID: 29480952.

28. Hoogwater FJH, Kuipers H, de Meijer VE, Maulat C, Muscari F, Polak WG, et al. 2023; Role of neoadjuvant chemoradiotherapy in liver transplantation for unresectable perihilar cholangiocarcinoma: multicentre, retrospective cohort study. BJS Open. 7:zrad025. DOI: 10.1093/bjsopen/zrad025. PMID: 37032423. PMCID: PMC10083139.

29. Mantel HT, Rosen CB, Heimbach JK, Nyberg SL, Ishitani MB, Andrews JC, et al. 2007; Vascular complications after orthotopic liver transplantation after neoadjuvant therapy for hilar cholangiocarcinoma. Liver Transpl. 13:1372–1381. DOI: 10.1002/lt.21107. PMID: 17427173.

30. Bagante F, Tran T, Spolverato G, Ruzzenente A, Buttner S, Ethun CG, et al. 2016; Perihilar cholangiocarcinoma: number of nodes examined and optimal lymph node prognostic scheme. J Am Coll Surg. 222:750–759.e2. DOI: 10.1016/j.jamcollsurg.2016.02.012. PMID: 27113512. PMCID: PMC5450030.

31. Rea DJ, Heimbach JK, Rosen CB, Haddock MG, Alberts SR, Kremers WK, et al. 2005; Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. Ann Surg. 242:451–458. discussion 458–461. DOI: 10.1097/01.sla.0000179678.13285.fa. PMID: 16135931. PMCID: PMC1357753.

32. Tan EK, Rosen CB, Heimbach JK, Gores GJ, Zamora-Valdes D, Taner T. 2020; Living donor liver transplantation for perihilar cholangiocarcinoma: outcomes and complications. J Am Coll Surg. 231:98–110. DOI: 10.1016/j.jamcollsurg.2019.12.037. PMID: 32035181.

33. Dondorf F, Uteβ F, Fahrner R, Felgendreff P, Ardelt M, Tautenhahn HM, et al. 2019; Liver transplant for perihilar cholangiocarcinoma (Klatskin tumor): the essential role of patient selection. Exp Clin Transplant. 17:363–369. DOI: 10.6002/ect.2018.0024. PMID: 29911960.

34. Azad AI, Rosen CB, Taner T, Heimbach JK, Gores GJ. 2020; Selected patients with unresectable perihilar cholangiocarcinoma (pCCA) derive long-term benefit from liver transplantation. Cancers (Basel). 12:3157. DOI: 10.3390/cancers12113157. PMID: 33121179. PMCID: PMC7693604.

35. Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, et al. 2021; Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:541–565. DOI: 10.6004/jnccn.2021.0022. PMID: 34030131.

36. Cambridge WA, Fairfield C, Powell JJ, Harrison EM, Søreide K, Wigmore SJ, et al. 2021; Meta-analysis and meta-regression of survival after liver transplantation for unresectable perihilar cholangiocarcinoma. Ann Surg. 273:240–250. DOI: 10.1097/SLA.0000000000003801. PMID: 32097164.

37. Kitajima T, Hibi T, Moonka D, Sapisochin G, Abouljoud MS, Nagai S. 2020; Center experience affects liver transplant outcomes in patients with hilar cholangiocarcinoma. ann surg oncol. 27:5209–5221. DOI: 10.1245/s10434-020-08682-5. PMID: 32495286.

38. Ethun CG, Lopez-Aguiar AG, Anderson DJ, Adams AB, Fields RC, Doyle MB, et al. 2018; Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg. 267:797–805. DOI: 10.1097/SLA.0000000000002574. PMID: 29064885. PMCID: PMC6002861.

39. Lerut J, Iesari S, Foguenne M, Lai Q. 2017; Hepatocellular cancer and recurrence after liver transplantation: what about the impact of immunosuppression? Transl Gastroenterol Hepatol. 2:80. DOI: 10.21037/tgh.2017.09.06. PMID: 29167827. PMCID: PMC5676205.

40. Schmelzle M, Benzing C, Fischer L, Herden U, Sterneck M, Settmacher U, et al. 2022; Feasibility and efficacy of adjuvant chemotherapy with gemcitabine after liver transplantation for perihilar cholangiocarcinoma - a multi-center, randomized, controlled trial (pro-duct001). Front Oncol. 12:910871. DOI: 10.3389/fonc.2022.910871. PMID: 36330499. PMCID: PMC9624225.

41. Moris D, Kostakis ID, Machairas N, Prodromidou A, Tsilimigras DI, Ravindra KV, et al. 2019; Comparison between liver transplantation and resection for hilar cholangiocarcinoma: a systematic review and meta-analysis. PLoS One. 14:e0220527. DOI: 10.1371/journal.pone.0220527. PMID: 31365594. PMCID: PMC6668826.

42. Breuer E, Mueller M, Doyle MB, Yang L, Darwish Murad S, Anwar IJ, et al. 2022; Liver transplantation as a new standard of care in patients with perihilar cholangiocarcinoma? Results from an international benchmark study. Ann Surg. 276:846–853. DOI: 10.1097/SLA.0000000000005641. PMID: 35894433. PMCID: PMC9983747.